| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4999 | T-10106 | Novel potent PPARγ antagonist with much improved drug-like properties and promising pharmacokinetic profile |
|
| DCC5000 | T16a(inh)-b01 | Selective class B inhibitor of the Ca -activated Cl- Channel, Ano1(TMEM16A) |
|
| DCC5001 | T16a(inh)-d01 | Selective class D inhibitor of the Ca -activated Cl- Channel, Ano1(TMEM16A) |
|
| DCC5002 | T-2 Toxin Triol | Type-A trichothecene mycotoxin |
|
| DCC5003 | T3ss Inhibitor Iii-7 | Novel inhibitor of the type III secretion system (T3SS), acting as a anti-microbial agent against Xanthomonas oryzae pv. oryzae (Xoo) |
|
| DCC5004 | t5660136 | Novel Inhibitor of Adenovirus Gene Transfer |
|
| DCC5005 | t5660138 | Novel Inhibitor of Adenovirus Gene Transfer |
|
| DCC5006 | T5975164 | Inhibitor of HIV-1 Assembly that Targets the Phosphatidylinositol (4,5)-bisphosphate Binding Site of the HIV-1 Matrix Protein |
|
| DCC5007 | T6603185 | Novel inhibitor of the catalytic functions of peroxiredoxin (Prx) and thioredoxin (Trx) systems |
|
| DCC5008 | Tachioside | Natural radical scavenger on ABTS |
|
| DCC5009 | Tachyplegina | Novel Inhibitor of Parasite Motility and Invasion |
|
| DCC5010 | Tachyplegina-2 | Novel Inhibitor of Parasite Motility and Invasion |
|
| DCC5011 | Tachyplegina-4 | Novel Irriversible Inhibitor of Parasite Motility and Invasion |
|
| DCC5012 | Tacrine-pyrimidone Hybrid 27g | Novel Potent Dual AChE/GSK-3 Inhibitor for the Treatment of Alzheimers Disease |
|
| DCC5013 | Tah-19 | Novel potent p53-MDM2/X antagonist, inhibiting MDM2 potently with a Ki value of 58 nmol/L, inducing accumulation of p53, p21 and MDM2, inhibiting cell cycle progression of U-2 OS cells at G1 phase in a p53-dependent manner |
|
| DCC5014 | Ta-in-2 | Novel inhibitor of the Klebsiella pneumoniae VapBC toxin-antitoxin (TA) system, acting as antimicrobial agents by disrupting the VapBC complex and activating VapC |
|
| DCC5015 | Tak-137 | Novel AMPA receptor potentiator with little agonistic effect, producing antidepressant-like effect without causing psychotomimetic effects |
|
| DCC5016 | tak-187 | Long-lasting ergosterol biosynthesis inhibitor |
|
| DCC5017 | Tak-21d | Potent FAAH Inhibitor |
|
| DCC5018 | Tak-220 Hydrochloride | Novel anti-HIV CCR5 antagonist |
|
| DCC5019 | Tak-233 | Novel selective 5-hydroxytryptamine type 2C (5-HT2C) receptor agonist |
|
| DCC5020 | Tak-418 | Novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A (LSD1) |
|
| DCC5021 | Talaroconvolutin A | Natural ferroptosis inducer, killing colorectal cancer cells in vitro and in vivo |
|
| DCC5022 | Talarozole | CYP26 inhibitor, potentiating the effects of all-trans retinoic acid on cultured human epidermal keratinocytes |
|
| DCC5023 | Talaumidin | Natural neurotrophic agent, promoting neurite outgrowth from neurons through PI3K/Akt pathway |
|
| DCC5024 | Talirine | Novel Antibody-Drug Conjugate PBD Dimer Payload |
|
| DCC5025 | Taltirelin | Superagonist at the human thyrotropin-releasing hormone receptor, reversing opioid-induced respiratory depression in isoflurane anesthetized rats |
|
| DCC5026 | Tamra-edatp | Novel Fluorescent dATP for DNA Synthesis In Vivo, exhibited high brightness, low toxicity, and rapid incorporation and depletion kinetics in both a vertebrate (zebrafish) and a nematode (Caenorhabditis elegans) |
|
| DCC5027 | Tan-67 | Potent and selective non-peptide δ1 opioid receptor agonist |
|
| DCC5028 | Tanshinol Borneol Ester | Novel angiogenesis stimulator, promoting multiple key steps of angiogenesis parially via Akt and MAPK signalling pathways, showing anti-ischemic and anti-atherosclerosis activities, also acting as a putative PPARγ agonist |
|
